Purpose: Based on exudative activity, choroidal neovascularization (CNV) in age-related macular degeneration (AMD) can be classified as “active” aCNV, pretherapied “silent” sCNV (i.e., a treatment-free interval >12 weeks), or treatment-naïve “quiescent” qCNV. We evaluated the qualitative and quantitative optical coherence tomography angiography (OCTA) features of these CNV subgroups. Methods: The presence of small-caliber vessels, peripheral arcades, and a -perilesional OCTA signal attenuation as well as values for vessel length, density, and branching index were evaluated for each CNV network in a 6 × 6 mm OCTA scan pattern. Results: Fifty-one eyes of 51 patients with AMD (age 75.9 ± 7.5 years; 20 males [39.2%]) were included. The qCNV subgroup (n = 8) showed the highest prevalence of qualitative and quantitative values for OCTA activity criteria, reaching significance with regard to small-caliber vessels (p = 0.003), peripheral arcades (p = 0.039), vessel length (p = 0.020), and branching index (p < 0.001) when compared to the aCNV (n = 32) and sCNV (n = 11) subgroups. Qualitative criteria were inversely associated with the number of previous anti-VEGF injections (each p < 0.03), while quantitative metrics also suggested lower values. Conclusions: These findings suggest that OCTA may be supportive in the phenotypical differentiation of CNV lesions secondary to AMD, while the assessed structural changes appeared to be more indicative of previously administered anti-VEGF therapy than current exudative activity.

1.
Lim
LS
,
Mitchell
P
,
Seddon
JM
,
Holz
FG
,
Wong
TY
.
Age-related macular degeneration
.
Lancet
.
2012
May
;
379
(
9827
):
1728
38
.
[PubMed]
0140-6736
2.
Rosenfeld
PJ
,
Brown
DM
,
Heier
JS
,
Boyer
DS
,
Kaiser
PK
,
Chung
CY
, et al.;
MARINA Study Group
.
Ranibizumab for neovascular age-related macular degeneration
.
N Engl J Med
.
2006
Oct
;
355
(
14
):
1419
31
.
[PubMed]
0028-4793
3.
Holz
FG
,
Tadayoni
R
,
Beatty
S
,
Berger
A
,
Cereda
MG
,
Cortez
R
, et al.
Multi-country real-life experience of anti-vascular endothelial growth factor therapy for wet age-related macular degeneration
.
Br J Ophthalmol
.
2015
Feb
;
99
(
2
):
220
6
.
[PubMed]
0007-1161
4.
Freund
KB
,
Zweifel
SA
,
Engelbert
M
.
Do we need a new classification for choroidal neovascularization in age-related macular degeneration?
Retina
.
2010
Oct
;
30
(
9
):
1333
49
.
[PubMed]
0275-004X
5.
von der Emde
L
,
Pfau
M
,
Thiele
S
,
Möller
PT
,
Hassenrik
R
,
Fleckenstein
M
, et al.
Mesopic and Dark-Adapted Two-Color Fundus-Controlled Perimetry in Choroidal Neovascularization Secondary to Age-Related Macular Degeneration
.
Transl Vis Sci Technol
.
2018
Jan
;
8
(
1
):
7
.
[PubMed]
2164-2591
6.
Lindner
M
,
Fang
PP
,
Steinberg
JS
,
Domdei
N
,
Pfau
M
,
Krohne
TU
, et al.
OCT Angiography-Based Detection and Quantification of the Neovascular Network in Exudative AMD
.
Invest Ophthalmol Vis Sci
.
2016
Nov
;
57
(
14
):
6342
8
.
[PubMed]
0146-0404
7.
Fang
PP
,
Harmening
WM
,
Müller
PL
,
Lindner
M
,
Krohne
TU
,
Holz
FG
.
[Technical principles of OCT angiography]
.
Ophthalmologe
.
2016
Jan
;
113
(
1
):
6
13
.
[PubMed]
0941-293X
8.
Jia
Y
,
Bailey
ST
,
Wilson
DJ
,
Tan
O
,
Klein
ML
,
Flaxel
CJ
, et al.
Quantitative optical coherence tomography angiography of choroidal neovascularization in age-related macular degeneration
.
Ophthalmology
.
2014
Jul
;
121
(
7
):
1435
44
.
[PubMed]
0161-6420
9.
Muakkassa
NW
,
Chin
AT
,
de Carlo
T
,
Klein
KA
,
Baumal
CR
,
Witkin
AJ
, et al.
Characterizing the effect of anti-vascular endothelial growth factor therapy on treatment-naive choroidal neovascularization using optical coherence tomography angiography
.
Retina
.
2015
Nov
;
35
(
11
):
2252
9
.
[PubMed]
0275-004X
10.
Kuehlewein
L
,
Sadda
SR
,
Sarraf
D
.
OCT angiography and sequential quantitative analysis of type 2 neovascularization after ranibizumab therapy
.
Eye (Lond)
.
2015
Jul
;
29
(
7
):
932
5
.
[PubMed]
0950-222X
11.
Coscas
GJ
,
Lupidi
M
,
Coscas
F
,
Cagini
C
,
Souied
EH
.
Optical coherence tomography angiography versus traditional multimodal imaging in assessing the activity of exudative age-related macular degeneration: a new diagnostic challenge
.
Retina
.
2015
Nov
;
35
(
11
):
2219
28
.
[PubMed]
0275-004X
12.
Roisman
L
,
Zhang
Q
,
Wang
RK
,
Gregori
G
,
Zhang
A
,
Chen
CL
, et al.
Optical Coherence Tomography Angiography of Asymptomatic Neovascularization in Intermediate Age-Related Macular Degeneration
.
Ophthalmology
.
2016
Jun
;
123
(
6
):
1309
19
.
[PubMed]
0161-6420
13.
Capuano
V
,
Miere
A
,
Querques
L
,
Sacconi
R
,
Carnevali
A
,
Amoroso
F
, et al.
Treatment-Naïve Quiescent Choroidal Neovascularization in Geographic Atrophy Secondary to Nonexudative Age-Related Macular Degeneration
.
Am J Ophthalmol
.
2017
Oct
;
182
:
45
55
.
[PubMed]
0002-9394
14.
Querques
G
,
Srour
M
,
Massamba
N
,
Georges
A
,
Ben Moussa
N
,
Rafaeli
O
, et al.
Functional characterization and multimodal imaging of treatment-naive “quiescent” choroidal neovascularization
.
Invest Ophthalmol Vis Sci
.
2013
Oct
;
54
(
10
):
6886
92
.
[PubMed]
0146-0404
15.
Carnevali
A
,
Cicinelli
MV
,
Capuano
V
,
Corvi
F
,
Mazzaferro
A
,
Querques
L
, et al.
Optical Coherence Tomography Angiography: A Useful Tool for Diagnosis of Treatment-Naïve Quiescent Choroidal Neovascularization
.
Am J Ophthalmol
.
2016
Sep
;
169
:
189
98
.
[PubMed]
0002-9394
16.
de Oliveira Dias
JR
,
Zhang
Q
,
Garcia
JM
,
Zheng
F
,
Motulsky
EH
,
Roisman
L
, et al.
Natural History of Subclinical Neovascularization in Nonexudative Age-Related Macular Degeneration Using Swept-Source OCT Angiography
.
Ophthalmology
.
2018
Feb
;
125
(
2
):
255
66
.
[PubMed]
0161-6420
17.
Lalwani
GA
,
Rosenfeld
PJ
,
Fung
AE
,
Dubovy
SR
,
Michels
S
,
Feuer
W
, et al.
A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO Study
.
Am J Ophthalmol
.
2009
Jul
;
148
(
1
):
43
58.e1
.
[PubMed]
0002-9394
18.
Told
R
,
Sacu
S
,
Hecht
A
,
Baratsits
M
,
Eibenberger
K
,
Kroh
ME
, et al.
Comparison of SD-Optical Coherence Tomography Angiography and Indocyanine Green Angiography in Type 1 and 2 Neovascular Age-related Macular Degeneration
.
Invest Ophthalmol Vis Sci
.
2018
May
;
59
(
6
):
2393
400
.
[PubMed]
0146-0404
19.
Macular Photocoagulation Study Group
.
Subfoveal neovascular lesions in age-related macular degeneration. Guidelines for evaluation and treatment in the macular photocoagulation study
.
Arch Ophthalmol
.
1991
Sep
;
109
(
9
):
1242
57
.
[PubMed]
0003-9950
20.
Zhang
Q
,
Chen
CL
,
Chu
Z
,
Zheng
F
,
Miller
A
,
Roisman
L
, et al.
Automated Quantitation of Choroidal Neovascularization: A Comparison Study Between Spectral-Domain and Swept-Source OCT Angiograms
.
Invest Ophthalmol Vis Sci
.
2017
Mar
;
58
(
3
):
1506
13
.
[PubMed]
0146-0404
21.
Zudaire
E
,
Gambardella
L
,
Kurcz
C
,
Vermeren
S
.
A computational tool for quantitative analysis of vascular networks
.
PLoS One
.
2011
;
6
(
11
):
e27385
.
[PubMed]
1932-6203
22.
Meyer
JH
,
Larsen
PP
,
Strack
C
,
Harmening
WM
,
Krohne
TU
,
Holz
FG
, et al.
Optical coherence tomography angiography (OCT-A) in an animal model of laser-induced choroidal neovascularization
.
Exp Eye Res
.
2019
Jul
;
184
:
162
71
.
[PubMed]
0014-4835
23.
R Core Team
. R: A language and Environment for Statistical Computing. R Foundation for Statistical Computing, Vienna, Austria.
2013
http://www.R-project.org
24.
Lupidi
M
,
Cerquaglia
A
,
Chhablani
J
,
Fiore
T
,
Singh
SR
,
Cardillo Piccolino
F
, et al.
Optical coherence tomography angiography in age-related macular degeneration: the game changer
.
Eur J Ophthalmol
.
2018
Jul
;
28
(
4
):
349
57
.
[PubMed]
1120-6721
25.
Miere
A
,
Querques
G
,
Semoun
O
,
Amoroso
F
,
Zambrowski
O
,
Chapron
T
, et al.
Optical coherence tomography angiography changes in early type 3 neovascularization after anti-vascular endothelial growth factor treatment
.
Retina
.
2017
Oct
;
37
(
10
):
1873
9
.
[PubMed]
0275-004X
26.
Kuehlewein
L
,
Bansal
M
,
Lenis
TL
,
Iafe
NA
,
Sadda
SR
,
Bonini Filho
MA
, et al.
Optical Coherence Tomography Angiography of Type 1 Neovascularization in Age-Related Macular Degeneration
.
Am J Ophthalmol
.
2015
Oct
;
160
(
4
):
739
48.e2
.
[PubMed]
0002-9394
27.
Sulzbacher
F
,
Pollreisz
A
,
Kaider
A
,
Kickinger
S
,
Sacu
S
,
Schmidt-Erfurth
U
;
Vienna Eye Study Center
.
Identification and clinical role of choroidal neovascularization characteristics based on optical coherence tomography angiography
.
Acta Ophthalmol
.
2017
Jun
;
95
(
4
):
414
20
.
[PubMed]
1755-375X
28.
El Ameen
A
,
Cohen
SY
,
Semoun
O
,
Miere
A
,
Srour
M
,
Quaranta-El Maftouhi
M
, et al.
Type 2 neovascularization secondary to age-related macular degeneration imaged by optical coherence tomography angiography
.
Retina
.
2015
Nov
;
35
(
11
):
2212
8
.
[PubMed]
0275-004X
29.
Coscas
G
,
Lupidi
M
,
Coscas
F
,
Français
C
,
Cagini
C
,
Souied
EH
.
Optical coherence tomography angiography during follow-up: qualitative and quantitative analysis of mixed type I and II choroidal neovascularization after vascular endothelial growth factor trap therapy
.
Ophthalmic Res
.
2015
;
54
(
2
):
57
63
.
[PubMed]
0030-3747
30.
Faatz
H
,
Rothaus
K
,
Gunnemann
F
,
Gutfleisch
M
,
Heimes-Bussmann
B
,
Lommatzsch
A
, et al.
[Changes in OCT Angiography of Type 2 CNV in Neovascular AMD during Anti-VEGF Treatment]
.
Klin Monbl Augenheilkd
.
2017
Sep
;
234
(
9
):
1125
31
.
[PubMed]
1439-3999
31.
Coscas
F
,
Cabral
D
,
Pereira
T
,
Geraldes
C
,
Narotamo
H
,
Miere
A
, et al.
Quantitative optical coherence tomography angiography biomarkers for neovascular age-related macular degeneration in remission
.
PLoS One
.
2018
Oct
;
13
(
10
):
e0205513
.
[PubMed]
1932-6203
32.
Al-Sheikh
M
,
Iafe
NA
,
Phasukkijwatana
N
,
Sadda
SR
,
Sarraf
D
.
Biomarkers of neovascular in age-related macular degeneration using optical coherence tomography angiography
.
Retina
.
2018
Feb
;
38
(
2
):
220
30
.
[PubMed]
0275-004X
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.